In this video lecture, Dr. Robert Sidonio Jr. discusses:
- How von Willebrand disease subtype, procedure type, and concentrate selection influence perioperative replacement therapy.
- The pharmacokinetic differences among plasma-derived and recombinant VWF concentrates, including their effects on factor VIII levels.
- How individualized and population pharmacokinetic approaches may improve dosing, monitoring, and safety during major surgery.
Dr. Robert Sidonio, Jr. MD, MSc. is the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorder of Emory, Medical Director of the Clinical Research Office at the Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta and Professor of Pediatrics and the Emory University School of Medicine, Atlanta, USA. He is the ATHN Chair, Medical HFA advisor and ISTH Clinical Chair of the ISTH 2027 Congress. His clinical research focuses on women and girls with bleeding disorders, von Willebrand disease and hemophilia A inhibitors and the extravascular distribution of clotting factor IX.
(Video Lecture Summary)
Introduction
Dr. Robert Sidonio Jr. reviews the pharmacokinetics of von Willebrand factor concentrate use, using the perioperative management of a patient with type 3 von Willebrand disease as a practical framework. He emphasizes that concentrate dosing in VWD is more complex than simply selecting a standard dose per kilogram. Clinicians must consider the patient’s disease subtype, the type of procedure, the specific concentrate available, the kinetics of both VWF and factor VIII, and the laboratory monitoring capabilities of the treating center.
A Major Surgery Case
The lecture begins with a 55-year-old woman with type 3 VWD who requires total knee arthroplasty. Her severe deficiency makes replacement therapy necessary for this major orthopedic procedure.
Dr. Sidonio stresses the importance of first confirming the VWD subtype. Patients with very low VWF levels may have type 3 VWD or another severe clearance phenotype, and accurate classification helps clinicians anticipate the response to treatment. The severity of the procedure must also be established because major surgery requires more intensive treatment and monitoring than minor procedures that may need only one dose or adjunctive therapy.
Treatment Options and Surgical Targets
Available treatment strategies include plasma-derived VWF concentrates, recombinant VWF, desmopressin in appropriate patients, and antifibrinolytic agents such as tranexamic acid or aminocaproic acid. More than one therapy is often used.
For major surgery, Dr. Sidonio describes an initial target close to 100% for VWF activity, followed by maintenance of adequate postoperative levels. Current recommendations generally suggest keeping both VWF and factor VIII above 50% for at least three days, although practice varies because the supporting evidence is limited.
Minor procedures usually require lower targets and may be managed with desmopressin, concentrate, tranexamic acid, or selected combinations. In patients with mild type 1 VWD or low VWF, a baseline level above 30%, and a mild bleeding phenotype, some minor mucosal procedures may be managed with tranexamic acid alone.
Laboratory Monitoring Challenges
One of the major practical barriers is the turnaround time for VWF assays. Factor VIII results are often available quickly, while VWF activity testing may not be performed daily or on weekends. Dr. Sidonio cautions against undertaking elective high-risk surgery when real-time monitoring is unavailable. Although clinicians may sometimes use factor VIII as a proxy because it is more accessible, factor VIII alone does not reliably reflect VWF levels. A patient may have a very high factor VIII level while VWF activity is approaching the lower end of the desired range.
This creates uncertainty about when and how much concentrate to redose. Careful planning with the laboratory and surgical team is therefore essential.
Available VWF Concentrates
Dr. Sidonio reviews several plasma-derived and recombinant concentrates, emphasizing that they differ in their VWF-to-factor VIII ratios, multimer composition, and pharmacokinetic behavior.
Recombinant VWF contains negligible factor VIII and includes ultra-large multimers because it has not been exposed to ADAMTS13 during production. It also has a relatively long half-life. Wilfactin similarly contains little factor VIII, although its multimer profile differs from recombinant VWF.
Common plasma-derived products include Humate-P, with a VWF activity-to-factor VIII ratio of approximately 2:1, and Wilate, with a ratio closer to 1:1. These differences mean that the same dose in units per kilogram can produce different VWF and factor VIII responses depending on the product. Dr. Sidonio does not suggest that one concentrate is universally superior. Instead, clinicians should understand the product available at their institution and adapt the dosing and monitoring plan accordingly.
The Relationship Between VWF and Factor VIII
VWF serves as a carrier protein for factor VIII and protects it from premature degradation and clearance. In the absence of VWF, factor VIII has a very short half-life. Once VWF is replaced, endogenous factor VIII becomes stabilized and may continue to rise. This relationship is especially important during repeated dosing. Some products produce a relatively parallel rise and decline in VWF and factor VIII. In other situations, VWF activity falls while factor VIII remains elevated or continues to accumulate.
Dr. Sidonio describes this divergent clearance as a major challenge. Clinicians may need to provide additional VWF but hesitate because factor VIII levels are already very high. Prolonged factor VIII levels above approximately 200% are a concern because of potential thrombotic risk.
Pharmacokinetic Principles
Pharmacokinetics describes how a therapy is distributed, metabolized, and eliminated. Important parameters include half-life, clearance, volume of distribution, area under the curve, in vivo recovery, and time above a therapeutic threshold. These parameters vary substantially among patients with VWD. Relevant factors include VWD subtype, baseline VWF level, body weight, blood group, age, and comorbidities. Surgical stress may initially increase the response, while operative bleeding and consumption may later reduce recovery.
Because of this variability, fixed dosing regimens may underexpose some patients and lead to bleeding while overexposing others and producing unnecessarily high factor levels.
Timing Recombinant or Low-Factor VIII Products
When using recombinant VWF or another concentrate containing little factor VIII, the timing of administration is particularly important. A dose may be given approximately 12 hours before surgery, allowing the infused VWF to stabilize endogenous factor VIII. Alternatively, it may be given closer to surgery with factor VIII checked before the procedure. Dr. Sidonio notes that many clinicians prefer administering VWF in advance so factor VIII has time to reach an adequate level.
After surgery, dosing frequency depends on measured levels and the desired targets. Some patients may require dosing up to twice daily, especially early in the postoperative course.
Calculating and Adjusting the Dose
For the surgical case, Dr. Sidonio demonstrates calculation of the initial dose based on the desired rise, the expected in vivo recovery, and the patient’s body weight. The calculated dose is then adjusted to account for anticipated surgical consumption. After the initial dose, VWF and factor VIII levels should be checked at planned intervals, often every 8 to 12 hours early in the postoperative period. Subsequent dosing should be adjusted according to the measured response rather than relying solely on a fixed schedule.
For the knee arthroplasty case, treatment would continue for approximately seven days, with additional on-demand support during physical therapy.
Population Pharmacokinetics
Traditional individual pharmacokinetic testing can require seven to ten blood samples across multiple infusions, making it burdensome for patients. Dr. Sidonio describes population pharmacokinetic modeling as a potential solution. This approach combines a small number of patient-specific samples with data from clinical trials and population models. The resulting curve can estimate the individual patient’s response without requiring intensive sampling.
Because VWD treatment involves both VWF and factor VIII, these models must account for the kinetics and interaction of both proteins. The goal is to enable individualized dosing that maintains effective hemostasis while avoiding excessive factor exposure, unnecessary concentrate use, and potentially avoidable thromboprophylaxis.
Multidisciplinary Planning
Dr. Sidonio emphasizes that successful perioperative management requires clear documentation and communication. The hematology team, surgeon, anesthesiologist, laboratory staff, nurses, and advanced practice providers should all understand the dosing schedule, timing of laboratory checks, target levels, and contingency plan.
The procedure should take place at a center capable of measuring the necessary factor levels and responding promptly to results. Careful coordination helps reduce unexpected problems during surgery and recovery.
Conclusion
Dr. Sidonio concludes that pharmacokinetic management of VWF concentrate requires more than applying a standard weight-based dose. Clinicians must know the patient’s VWD subtype, understand the concentrate being used, establish appropriate targets, and monitor both VWF and factor VIII.
Individualized dosing and emerging population pharmacokinetic models may improve consistency, limit under- and overexposure, and support safer perioperative care for patients with VWD.